1. Home
  2. TBPH vs NGL Comparison

TBPH vs NGL Comparison

Compare TBPH & NGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TBPH
  • NGL
  • Stock Information
  • Founded
  • TBPH 2013
  • NGL 1940
  • Country
  • TBPH United States
  • NGL United States
  • Employees
  • TBPH N/A
  • NGL N/A
  • Industry
  • TBPH Biotechnology: Pharmaceutical Preparations
  • NGL Natural Gas Distribution
  • Sector
  • TBPH Health Care
  • NGL Utilities
  • Exchange
  • TBPH Nasdaq
  • NGL Nasdaq
  • Market Cap
  • TBPH 536.5M
  • NGL 446.2M
  • IPO Year
  • TBPH N/A
  • NGL 2011
  • Fundamental
  • Price
  • TBPH $10.90
  • NGL $4.13
  • Analyst Decision
  • TBPH Strong Buy
  • NGL
  • Analyst Count
  • TBPH 5
  • NGL 0
  • Target Price
  • TBPH $16.60
  • NGL N/A
  • AVG Volume (30 Days)
  • TBPH 158.6K
  • NGL 429.1K
  • Earning Date
  • TBPH 08-12-2025
  • NGL 08-07-2025
  • Dividend Yield
  • TBPH N/A
  • NGL N/A
  • EPS Growth
  • TBPH N/A
  • NGL N/A
  • EPS
  • TBPH N/A
  • NGL N/A
  • Revenue
  • TBPH $65,266,000.00
  • NGL $3,469,186,000.00
  • Revenue This Year
  • TBPH $51.74
  • NGL N/A
  • Revenue Next Year
  • TBPH N/A
  • NGL N/A
  • P/E Ratio
  • TBPH N/A
  • NGL N/A
  • Revenue Growth
  • TBPH 6.11
  • NGL N/A
  • 52 Week Low
  • TBPH $7.44
  • NGL $2.64
  • 52 Week High
  • TBPH $11.88
  • NGL $5.73
  • Technical
  • Relative Strength Index (RSI)
  • TBPH 45.21
  • NGL 43.74
  • Support Level
  • TBPH $10.90
  • NGL $4.17
  • Resistance Level
  • TBPH $11.26
  • NGL $4.40
  • Average True Range (ATR)
  • TBPH 0.24
  • NGL 0.14
  • MACD
  • TBPH -0.08
  • NGL -0.03
  • Stochastic Oscillator
  • TBPH 2.00
  • NGL 19.51

About TBPH Theravance Biopharma Inc.

Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).

About NGL NGL ENERGY PARTNERS LP Common Units representing Limited Partner Interests

NGL Energy Partners LP is a USA-based firm that owns and operates a vertically integrated energy business. The company's operating segments include Crude Oil Logistics, Water Solutions, and Liquids Logistics. It operates crude oil Logistics, owns pipeline injection stations, and offers services for the treatment and disposal of wastewater generated from crude oil and natural gas production, as well as for the disposal of solids, such as tank bottoms and drilling fluids. The firm also supplies natural gas liquids to retailers, wholesalers, refiners, and petrochemical plants and sells propane and distillates.

Share on Social Networks: